Endothelial Graft Rejection Clinical Trial
| NCT number | NCT01028443 |
| Other study ID # | 8546 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 4 |
| First received | December 8, 2009 |
| Last updated | December 8, 2009 |
| Verified date | April 2006 |
| Source | hahid Beheshti University of Medical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Iran: Ethics Committee |
| Study type | Interventional |
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Penetrating keratoplasty in eyes without vascularization Exclusion Criteria: - History of previous intraocular surgery |
N/A
| Country | Name | City | State |
|---|---|---|---|
| Iran, Islamic Republic of | Ophthalmic Research Center | Tehran | |
| Iran, Islamic Republic of | Ophthalmic Research Center | Tehran |
| Lead Sponsor | Collaborator |
|---|---|
| hahid Beheshti University of Medical Sciences |
Iran, Islamic Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The rate of rejection after drop sessation | 3 years | Yes |